Wojciech Cytawa1,2, Anna Katharina Seitz3, Stefan Kircher4, Kazuhito Fukushima2, Johannes Tran-Gia2, Andreas Schirbel2, Tomasz Bandurski5, Piotr Lass1, Markus Krebs3, Wojciech Połom6, Marcin Matuszewski6, Hans-Jürgen Wester7, Andreas K Buck2, Hubert Kübler3, Constantin Lapa8. 1. Department of Nuclear Medicine, Medical University of Gdańsk, Smoluchowskiego Str. 17, 80-952, Gdańsk, Poland. 2. Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany. 3. Department of Urology, University Hospital Würzburg, Würzburg, Germany. 4. Institute of Pathology, Comprehensive Cancer Center Mainfranken (CCCMF), University of Würzburg, Würzburg, Germany. 5. Department of Radiology Informatics and Statistics, Medical University of Gdańsk, Gdańsk, Poland. 6. Department of Urology, Medical University of Gdansk, Gdańsk, Poland. 7. Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany. 8. Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany. Lapa_C@ukw.de.
Abstract
PURPOSE: The present study is based on a retrospective analysis of Gallium-68 (68Ga)-labelled prostate-specific membrane antigen (68Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment. METHODS: A total of 82 men were included in the study and were imaged with 68Ga-PSMA I&T PET/CT to assess the distribution of PSMA-avid disease for staging purposes (11 with low-risk, 32 with intermediate-risk, and 39 with high-risk PCa). Forty patients (20 with intermediate- and 20 with high-risk disease) underwent subsequent radical prostatectomy with extended pelvic lymph node dissection which allowed for correlation of imaging findings with histopathologic data. RESULTS: PSMA-positive disease was detected in 83% of patients with 66/82 (80.5%) primary tumours being visualized. PSMA-avid lymph nodes were recorded in 17/82 patients (20.7%, 3 with intermediate-risk and 14 with high-risk PCa); distant disease was found in 14/82 subjects (17.1%, 2 with intermediate-risk and 12 with high-risk PCa). No extraprostatic disease was found in low-risk PCa. SUVmax of primary tumours showed a weak but significant correlation with serum PSA values (r = 0.51, p < 0.001) and Gleason scores (GSC; r = 0.35, p = 0.001), respectively. In correlation with histopathology, calculated per-region sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of lymph node metastases were 35.0%, 98.4%, 63.6%, 95.0%, and 93.0%, respectively. CONCLUSIONS: In patients with initial diagnosis of intermediate- and high-risk prostate cancer, 68Ga-PSMA I&T PET/CT emerges as a relevant staging procedure by identifying nodal and/or distant metastases. Due to the low prevalence of extraprostatic disease, its value seems to be limited in low-risk disease.
PURPOSE: The present study is based on a retrospective analysis of Gallium-68 (68Ga)-labelled prostate-specific membrane antigen (68Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment. METHODS: A total of 82 men were included in the study and were imaged with 68Ga-PSMA I&T PET/CT to assess the distribution of PSMA-avid disease for staging purposes (11 with low-risk, 32 with intermediate-risk, and 39 with high-risk PCa). Forty patients (20 with intermediate- and 20 with high-risk disease) underwent subsequent radical prostatectomy with extended pelvic lymph node dissection which allowed for correlation of imaging findings with histopathologic data. RESULTS:PSMA-positive disease was detected in 83% of patients with 66/82 (80.5%) primary tumours being visualized. PSMA-avid lymph nodes were recorded in 17/82 patients (20.7%, 3 with intermediate-risk and 14 with high-risk PCa); distant disease was found in 14/82 subjects (17.1%, 2 with intermediate-risk and 12 with high-risk PCa). No extraprostatic disease was found in low-risk PCa. SUVmax of primary tumours showed a weak but significant correlation with serum PSA values (r = 0.51, p < 0.001) and Gleason scores (GSC; r = 0.35, p = 0.001), respectively. In correlation with histopathology, calculated per-region sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of lymph node metastases were 35.0%, 98.4%, 63.6%, 95.0%, and 93.0%, respectively. CONCLUSIONS: In patients with initial diagnosis of intermediate- and high-risk prostate cancer, 68Ga-PSMA I&T PET/CT emerges as a relevant staging procedure by identifying nodal and/or distant metastases. Due to the low prevalence of extraprostatic disease, its value seems to be limited in low-risk disease.
Entities:
Keywords:
68Ga-PSMA I&T; PET/CT; PSMA; Primary staging; Prostate cancer
Authors: Christian Schmidkonz; Michael Cordes; Michael Beck; Theresa Ida Goetz; Daniela Schmidt; Olaf Prante; Tobias Bäuerle; Michael Uder; Bernd Wullich; Peter Goebell; Torsten Kuwert; Philipp Ritt Journal: Clin Nucl Med Date: 2018-04 Impact factor: 7.794
Authors: Spencer C Behr; Rahul Aggarwal; Henry F VanBrocklin; Robert R Flavell; Kenneth Gao; Eric J Small; Joseph Blecha; Salma Jivan; Thomas A Hope; Jeffry P Simko; John Kurhanewicz; Susan M Noworolski; Natalie J Korn; Romelyn De Los Santos; Matthew R Cooperberg; Peter R Carroll; Hao G Nguyen; Kirsten L Greene; Beatrice Langton-Webster; Clifford E Berkman; Youngho Seo Journal: J Nucl Med Date: 2018-11-21 Impact factor: 10.057
Authors: Sebastian Schmuck; Christoph A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Firas Abdollah; Giorgio Gandaglia; Nazareno Suardi; Umberto Capitanio; Andrea Salonia; Alessandro Nini; Marco Moschini; Maxine Sun; Pierre I Karakiewicz; Sharhokh F Shariat; Francesco Montorsi; Alberto Briganti Journal: Eur Urol Date: 2014-06-02 Impact factor: 20.096
Authors: Christina Laschinsky; Ken Herrmann; Wolfgang Fendler; Michael Nader; Harald Lahner; Boris Hadaschik; Patrick Sandach Journal: Radiologie (Heidelb) Date: 2022-10
Authors: Wojciech Cytawa; Stefan Kircher; Hubert Kübler; Rudolf A Werner; Simon Weber; Philipp Hartrampf; Tomasz Bandurski; Piotr Lass; Wojciech Połom; Marcin Matuszewski; Hans-Jürgen Wester; Constantin Lapa; Andreas Rosenwald; Anna Katharina Seitz; Andreas K Buck Journal: Eur J Nucl Med Mol Imaging Date: 2022-05-12 Impact factor: 10.057
Authors: Fernando Sabino M Monteiro; Juçara Motta Serafim Eliam; Rafaela Gomes de Jesus; Pedro Cavalcante; Gustavo do Vale Gomes; Bruno Hochhegger; Vinicius K Gonçalves; Laura Von Wallwitz Freitas; Diego H Roman; Andre Poisl Fay Journal: Prostate Int Date: 2020-08-13
Authors: B H E Jansen; Y J L Bodar; G J C Zwezerijnen; D Meijer; J P van der Voorn; J A Nieuwenhuijzen; M Wondergem; T A Roeleveld; R Boellaard; O S Hoekstra; R J A van Moorselaar; D E Oprea-Lager; A N Vis Journal: Eur J Nucl Med Mol Imaging Date: 2020-08-12 Impact factor: 9.236
Authors: Falk Gühne; Stefanie Radke; Thomas Winkens; Christian Kühnel; Julia Greiser; Philipp Seifert; Robert Drescher; Martin Freesmeyer Journal: Pharmaceuticals (Basel) Date: 2021-12-22
Authors: Patrick W Mihatsch; Matthias Beissert; Martin G Pomper; Thorsten A Bley; Anna K Seitz; Hubert Kübler; Andreas K Buck; Steven P Rowe; Sebastian E Serfling; Philipp E Hartrampf; Rudolf A Werner Journal: Cancers (Basel) Date: 2022-01-06 Impact factor: 6.639